Vindesine in advanced renal cancer. A study of the EORTC genito-urinary tract cancer cooperative group

Sophie D. Fossa, Louis Denis, Allan T. Van Oosterom, Marleen De Pauw, Gerrit Stoter

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Vindesine at a dose of 3 mg/m2 i.v. once a week failed to produce responses in 24 adequately treated patients with measurable advanced renal carcinoma. Leukopenia and peripheral neurotoxicity were the most often observed side-effects. On the basis of the negative result, the application of vindesine in this disease is not recommended.

Original languageEnglish (US)
Pages (from-to)473-475
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume19
Issue number4
DOIs
StatePublished - Jan 1 1983

Fingerprint

Urogenital Neoplasms
Vindesine
Urologic Neoplasms
Kidney Neoplasms
Leukopenia
Carcinoma
Kidney

ASJC Scopus subject areas

  • Oncology

Cite this

Vindesine in advanced renal cancer. A study of the EORTC genito-urinary tract cancer cooperative group. / Fossa, Sophie D.; Denis, Louis; Van Oosterom, Allan T.; De Pauw, Marleen; Stoter, Gerrit.

In: European Journal of Cancer and Clinical Oncology, Vol. 19, No. 4, 01.01.1983, p. 473-475.

Research output: Contribution to journalArticle

Fossa, Sophie D. ; Denis, Louis ; Van Oosterom, Allan T. ; De Pauw, Marleen ; Stoter, Gerrit. / Vindesine in advanced renal cancer. A study of the EORTC genito-urinary tract cancer cooperative group. In: European Journal of Cancer and Clinical Oncology. 1983 ; Vol. 19, No. 4. pp. 473-475.
@article{eff06fa1e9f24df583ffa9a06ee5a536,
title = "Vindesine in advanced renal cancer. A study of the EORTC genito-urinary tract cancer cooperative group",
abstract = "Vindesine at a dose of 3 mg/m2 i.v. once a week failed to produce responses in 24 adequately treated patients with measurable advanced renal carcinoma. Leukopenia and peripheral neurotoxicity were the most often observed side-effects. On the basis of the negative result, the application of vindesine in this disease is not recommended.",
author = "Fossa, {Sophie D.} and Louis Denis and {Van Oosterom}, {Allan T.} and {De Pauw}, Marleen and Gerrit Stoter",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/0277-5379(83)90109-8",
language = "English (US)",
volume = "19",
pages = "473--475",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "4",

}

TY - JOUR

T1 - Vindesine in advanced renal cancer. A study of the EORTC genito-urinary tract cancer cooperative group

AU - Fossa, Sophie D.

AU - Denis, Louis

AU - Van Oosterom, Allan T.

AU - De Pauw, Marleen

AU - Stoter, Gerrit

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Vindesine at a dose of 3 mg/m2 i.v. once a week failed to produce responses in 24 adequately treated patients with measurable advanced renal carcinoma. Leukopenia and peripheral neurotoxicity were the most often observed side-effects. On the basis of the negative result, the application of vindesine in this disease is not recommended.

AB - Vindesine at a dose of 3 mg/m2 i.v. once a week failed to produce responses in 24 adequately treated patients with measurable advanced renal carcinoma. Leukopenia and peripheral neurotoxicity were the most often observed side-effects. On the basis of the negative result, the application of vindesine in this disease is not recommended.

UR - http://www.scopus.com/inward/record.url?scp=0020580410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020580410&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(83)90109-8

DO - 10.1016/0277-5379(83)90109-8

M3 - Article

C2 - 6305668

AN - SCOPUS:0020580410

VL - 19

SP - 473

EP - 475

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 4

ER -